| 摘要 |
The present application describes treatment of non-malignant indications, su ch as psoriasis, endometriosis, scleroderma, vascular diseases or disorders, respiratory disease, colon polyps or fibroadenoma, with anti-ErbB2 antibodie s (e.g. rhuMAb 2C4).
|
